Brought to you by 
Sun Pharmaceutical licenses exclusive rights to Merck's Phase III psoriasis candidate
02 Oct 2014
Executive Summary
Merck & Co. Inc. granted Indian drug company Sun Pharmaceutical Industries Ltd. exclusive worldwide rights to tildrakizumab (MK3222) for all human indications; the therapy is in Phase III trials for chronic plaque psoriasis.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sun Pharmaceutical licenses exclusive rights to Merck's Phase III psoriasis candidate
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice